Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from ...

An FDA approval put Ki-67 scoring — which may predict tumor growth — in the spotlight, but what that means long term to patients depends on who you ask. The speed at which cancer cells grow can be an ...